Beacon Biosignals has developed an AI-driven EEG headband that monitors brain activity during sleep, offering new opportunities for diagnosing and treating neurological disorders outside traditional labs. The technology, already used in numerous clinical trials, provides high-quality data for drug development and disease detection.
AI-driven approaches are enabling faster and more informed decision-making in clinical trials, helping pharmaceutical companies like Novartis optimize drug development. By integrating patient-level data and modeling, enterprises can improve trial design and allocation of resources. This development is reshaping the economics and effectiveness of modern drug discovery.
A new open standard, AGENTS.md, is providing AI coding assistants with critical project context in the pharmaverse ecosystem for clinical R programming. The standard aims to ensure that AI-generated code aligns with highly specific regulatory and domain expectations. Adoption within pharmaverse packages, including {admiral}, is already shaping workflows and informing wider open-source policy discussions.
Zurich-based Rivia has secured $15 million in Series A funding to improve the fragmented data infrastructure of clinical trials. The company is developing a unified data engine and embedded AI agents aimed at streamlining trial workflows, reducing costs, and accelerating medical innovation. The funding comes at a time when regulatory pressures and declining industry returns are prompting a need for more efficient trial operations.
Life sciences companies face significant challenges in scaling generative AI due to insufficient data maturity and fragmented data sources. Experts highlight the need for robust data infrastructures, standardized evaluation benchmarks, and organizational alignment to unlock the full potential of AI in R&D workflows.
Barcelona-based Biorce has raised $52 million in a Series A round to accelerate the international rollout of its AI-driven clinical trial platform, Aika. The funding will be used to advance the company's AI infrastructure, streamline trial design, and expand operations, notably in the United States.
Bristol Myers Squibb (BMS), a global leader in biopharmaceuticals, is pioneering artificial intelligence (AI) solutions to transform the management of clinical trials and streamline internal talent development. By integrating advanced machine learning in patient-trial matching and launching a skills-based AI-powered talent marketplace, BMS is redefining operational efficiency and workforce agility.
AI technologies are transforming clinical trial workflows, aiming to shorten timelines and enhance efficiency in pharmaceutical R&D. Bayer's Patricio La Rosa discusses the practical challenges of integrating AI, including scalability, regulatory hurdles, cybersecurity, and new incentive models for patient data use.
Stay informed with curated insights delivered weekly to your inbox.